European Commission approves final marketing authorization for Suliqua

The European Commission (EC) has approved the marketing authorization for Suliqua, Sanofi's (SAN) combination therapy for type 2 diabetes. This approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the EMA in November 2016, and was finalized on January 11, 2017. Suliqua is a fixed-ratio combination of insulin glargine (100U), a basal insulin, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, used in the treatment of diabetes. With this approval, Sanofi now has the regulatory framework in place to offer a new treatment option to adult patients with type 2 diabetes in the European Union whose blood sugar is not adequately controlled with oral antidiabetic agents.

Demonstrated superior efficacy based on Phase 3 clinical data

The European approval of Suliqua is based on the results of the LixiLan-O and LixiLan-L Phase 3 clinical trials, which involved approximately 1,900 patients. In the LixiLan-L trial, which analyzed patients with type 2 diabetes whose blood sugar was not adequately controlled with basal insulin therapy, the Suliqua group showed an average reduction of 1.1% in HbA1c levels, demonstrating superior blood sugar control compared to the insulin glargine alone group (0.6% reduction). In particular, the GLP-1 component counteracted the common side effect of basal insulin, weight gain, resulting in a significant weight loss of approximately 1.4 kg compared to the control group. This clinical efficacy suggests that Suliqua has high clinical utility for elderly patients and overweight patients with diabetes who are at high risk of cardiovascular and metabolic complications.

Changes in the insulin market and commercial value

As type 2 diabetes progresses, combination therapy becomes essential, and a combination product that targets two hormone pathways simultaneously with a single injection significantly improves patient compliance. By acting simultaneously on the insulin receptor and the GLP-1 receptor, Suliqua provides a mechanism to control both fasting and postprandial blood sugar levels. This approval, obtained at a time when the diabetes treatment market is shifting from single-ingredient injectables to combination injectables, will be a key asset in defending Sanofi's metabolic disease portfolio. With regulatory hurdles cleared and commercial launch possible throughout Europe, long-term revenue growth is expected.

Strategy in response to competitive landscape and intensifying market competition

However, Suliqua faces the challenge of competing for market share with Novo Nordisk's Xultophy in the European market. Xultophy (a combination of insulin degludec and liraglutide) has already entered the European market and, as of 2017, recorded sales of approximately 729 million Danish kroner (approximately $115 million), demonstrating its first-mover advantage. Sanofi, as a latecomer, is expected to implement a sales strategy that leverages its price competitiveness and the brand recognition of its globally used basal insulin, Lantus, to expand its market share. In particular, as the clinical paradigm for diabetes treatment shifts towards recommending GLP-1 agonists first, demonstrating the value of a fixed-ratio combination will be a key to future sales.

Why it matters

Sanofi's European approval of Suliqua is a milestone that officially demonstrates the clinical Phase 3 (Approval stage) competitiveness of a late-stage fixed-ratio combination injectable in the global type 2 diabetes treatment market, which has approximately 462 million patients. In the short term, it is expected to directly target the European market, which has annual sales of hundreds of millions of dollars and is currently dominated by Novo Nordisk's Xultophy, by highlighting its efficacy in reducing HbA1c by 1.1% and suppressing weight gain. In the medium to long term, it will function as a key replacement for Lantus, Sanofi's blockbuster basal insulin, whose patent is expiring, and will contribute to defending Sanofi's metabolic disease division. However, as guidelines are increasingly recommending single GLP-1 agonists first, additional clinical studies to demonstrate the treatment sequence competitiveness of the combination product will be a key monitoring factor for institutional investors.